Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.

Department of Ophthalmology and Visual Science, College of Medicine, Clinical Research Institute, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea.
Clinical and Experimental Ophthalmology (Impact Factor: 1.96). 05/2012; DOI: 10.1111/j.1442-9071.2012.02813.x
Source: PubMed

ABSTRACT Background:  This study was conducted to evaluate the effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of laser-induced choroidal neovascularization (CNV). Methods:  CNV was induced in C57BL/6 mice by rupturing Bruch's membrane using laser photocoagulation. Following laser injury, the mice were divided into three groups and administered either vehicle, 1 mg/kg or 5 mg/kg of cediranib daily by oral gavage for two weeks. Two weeks after laser injury, the area of CNV lesions were measured by choroidal flat mounts using fluorescein-labeled dextran. Immunofluorescence staining with isolectin IB4 was also used to quantify the CNV lesions. Results:  Choroidal flat mount analysis revealed that orally administered cediranib reduced the extent of CNV. The groups treated with 1 and 5 mg/kg/day showed 57.2 and 66.0 % reduction of CNV lesions, respectively, compared to the control group treated with vehicle alone (P = 0.012). The size of the fluorescently labeled CNV complex in cediranib-treated groups was much smaller than that from vehicle-treated group (P = 0.035). Conclusions:  Cediranib inhibited laser-induced CNV in mice and may have therapeutic potential for patients with neovascular age-related macular degeneration. © 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The elucidation of the molecular pathogenesis of a disease in animal models provides candidate targets for treatment. As specific antagonists for a target are developed and tested in clinical trials, if benefit is achieved, the candidate becomes a validated target. Validated targets stimulate additional research to identify optimal ways of attacking the target and studies in related disease processes to determine if the molecule is also a target in that context. Vascular endothelial growth factor (VEGF) has been identified as a validated target for several retinal vascular diseases. This has led to a flurry of activity resulting in beneficial treatments for patients and intensification of the search for other targets. This review summarizes preclinical and clinical trial results obtained with VEGF antagonists and describes evidence supporting the candidacy of other molecules currently being tested or soon to be tested for target status.
    Journal of Cellular Physiology 04/2007; 210(3):575-81. · 4.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To report on the effect of oral nexavar (Sorafenib) treatment in one patient with neovascular age-related macular degeneration (AMD) and advanced renal cell cancer (RCC). After two intravitreal injections of bevacizumab (1.25 mg) for occult choroidal neovascularization (CNV) in AMD, the patient was started on oral Sorafenib (400 mg twice daily) treatment for RCC. Visual acuity (VA) was 20/80 in the left eye and optical coherence tomography (OCT) demonstrated persistent central thickening to 251 microm after bevacizumab. After 6 weeks of oral Sorafenib treatment, VA had increased to 20/70 and a significant decrease in retinal thickness to 208 microm was observed on OCT. The patient remained stable during a further 3 months of follow-up. Resolution of macular oedema and stabilization of VA under oral treatment with the multikinase inhibitor Sorafenib was observed. This observation warrants further investigation.
    Acta ophthalmologica 07/2008; 86(4):456-8. · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Age-related macular degeneration (AMD) is one of the four most common causes of blindness in the United States. Retinal manifestations of AMD can be categorized as either atrophic or neovascular/exudative. To the best of our knowledge, the proportion of patients legally blind due to the neovascular/exudative manifestations of this disease has not been previously reported. Data from two studies, the Framingham Eye Study and a large case-control study, demonstrate that the vast majority of patients with legal blindness due to AMD have the neovascular/exudative form of the disease. Seventy-nine percent of eyes legally blind due to AMD in the Framingham population and 90% of eyes legally blind due to AMD in the case-control study had neovascular/exudative retinopathy. This is in spite of the fact that neovascular/exudative retinopathy is a relatively infrequent complication of AMD.
    Archives of Ophthalmology 12/1984; 102(11):1640-2. · 3.83 Impact Factor


1 Download